Hepatic Function and liver impairment
Sagimet Biosciences Inc. is involved in clinical research centered on impaired hepatic function, with interest in how mild, moderate, and severe hepatic impairment relate to normal liver function. The study population includes healthy volunteers alongside participants with Child-Pugh A, Child-Pugh B, and Child-Pugh C classifications.
- Normal hepatic function
- Mild hepatic impairment
- Moderate hepatic impairment
- Severe hepatic impairment
The sponsor’s research activity is directed toward understanding hepatic impairment across a range of liver disease severity categories in a human pharmacology setting.
Pharmacokinetics and drug handling
The funded clinical work includes evaluation of pharmacokinetic behavior in subjects with differing levels of hepatic impairment, reflecting an interest in how liver dysfunction may alter drug disposition. This area is closely tied to assessing medication behavior in both healthy subjects and those with compromised hepatic function.
- Pharmacokinetic assessment
- Drug disposition
- Hepatic metabolism
- Healthy subject comparison
Clinical interest in this domain focuses on comparative pharmacology across normal and impaired liver function groups.
Metabolic liver disease and fatty liver research
The sponsor’s therapeutic focus aligns with liver-related metabolic disorders, particularly conditions associated with abnormal hepatic function and altered metabolic regulation. This places emphasis on clinical questions relevant to fatty liver disease and broader metabolic liver pathology.
- Metabolic dysfunction
- Fatty liver disease
- Hepatic metabolic processes
- Liver disease characterization
Research in this area is centered on liver-centered therapeutic development within a metabolic disease framework.
Clinical pharmacology in special populations
Sagimet Biosciences Inc. supports studies involving participants with special hepatic populations, including those with graded liver impairment. This reflects interest in clinical pharmacology questions that arise when evaluating treatment behavior in individuals with altered organ function.
- Special population studies
- Hepatic impairment classification
- Organ function variability
- Comparative liver assessment
The research landscape includes attention to subject stratification by hepatic status in a controlled clinical setting.
